Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more
Zentalis Pharmaceuticals Llc (ZNTL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.107x
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has a cash flow conversion efficiency ratio of -0.107x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.96 Million) by net assets ($252.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zentalis Pharmaceuticals Llc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Zentalis Pharmaceuticals Llc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zentalis Pharmaceuticals Llc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Xinan Technology Co. Ltd. A
SHE:301170
|
N/A |
|
Hansa Biopharma AB
ST:HNSA
|
0.253x |
|
EKF Diagnostics Holdings plc
PINK:EKDHF
|
0.068x |
|
Theratechnologies Inc.
NASDAQ:THTX
|
-0.444x |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
0.347x |
|
HUA YU LIEN Development Co Ltd
TW:1436
|
-0.040x |
|
Cape Industries Ltd
KQ:064820
|
0.310x |
|
Digital Imaging Technology INC
KQ:110990
|
0.003x |
Annual Cash Flow Conversion Efficiency for Zentalis Pharmaceuticals Llc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Zentalis Pharmaceuticals Llc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $337.19 Million | $-170.86 Million | -0.507x | -6.65% |
| 2023-12-31 | $437.39 Million | $-207.82 Million | -0.475x | -25.94% |
| 2022-12-31 | $434.02 Million | $-163.75 Million | -0.377x | +10.76% |
| 2021-12-31 | $364.48 Million | $-154.09 Million | -0.423x | -62.33% |
| 2020-12-31 | $333.38 Million | $-86.83 Million | -0.260x | +54.48% |
| 2019-12-31 | $68.42 Million | $-39.14 Million | -0.572x | +23.79% |
| 2018-12-31 | $32.31 Million | $-24.25 Million | -0.751x | -- |